论文部分内容阅读
目的观察莫西沙星联合氨溴索在治疗慢性支气管炎急性发作时的疗效,观察患者体内的白介素、肿瘤坏死因子受影响情况。方法选取2014年2月-2015年10月慢性支气管炎急性发作期的患者172例,随机分为观察组和对照组各86例。治疗期间,2组患者除给予常规吸氧、解痉平喘药物外,不再服用其他黏液溶解药,同时给予每组患者莫西沙星注射液静脉滴注,观察组加用盐酸氨溴索雾化吸入。测定治疗前后2组患者血清和痰上清液中的TNF-α、IL-6、IL-8水平。结果治疗后2组血清和痰上清液中TNF-α、IL-6、IL-8水平较治疗前均有明显下降,且观察组较对照组下降程度更明显,差异有统计学意义(P<0.05)。观察组的有效率为95.35%显著高于对照组的80.23%,差异有统计学意义(P<0.05)。结论莫西沙星联合氨溴索可以有效降低慢性支气管炎急性发作患者的白介素和肿瘤坏死因子水平,可有效减轻炎性反应,缓解临床症状。
Objective To observe the efficacy of moxifloxacin combined with ambroxol in the treatment of acute exacerbation of chronic bronchitis and observe the effects of interleukin and tumor necrosis factor in the patients. Methods A total of 172 patients with acute exacerbation of chronic bronchitis from February 2014 to October 2015 were randomly divided into observation group (86 cases) and control group (86 cases). During the treatment, two groups of patients except the conventional oxygen inhalation, antispasmodic antiasthmatic drugs, no longer take other mucolytic drugs, while giving each group moxifloxacin intravenous injection, the observation group plus ambroxol hydrochloride inhalation . The levels of TNF-α, IL-6 and IL-8 in serum and sputum supernatant of two groups before and after treatment were measured. Results After treatment, the levels of TNF-α, IL-6 and IL-8 in serum and sputum supernatant of the two groups were significantly lower than those before treatment, and the degree of decrease in the observation group was more obvious than that in the control group (P <0.05). The effective rate of the observation group was 95.35%, which was significantly higher than that of the control group (80.23%), the difference was statistically significant (P <0.05). Conclusion Moxifloxacin combined with ambroxol can effectively reduce the levels of interleukin and tumor necrosis factor in the patients with acute exacerbation of chronic bronchitis, which can effectively reduce the inflammatory reaction and relieve the clinical symptoms.